Background: Hyperkalemia occurs frequently in diabetes. Sodium zirconium cyclosilicate (SZC), an oral, selective potassium (K) binder, rapidly reduces K in patients (pts) with hyperkalemia and has been shown to maintain normokalemia for up to 1 y. We compared the response to SZC in adults with and without diabetes mellitus (DM, type 1/2) in a 12 [...]